NCT04517266 is a NA clinical trial of omit of IMI group in Breast Cancer, sponsored by Ruijin Hospital.

Who is sponsoring NCT04517266?

NCT04517266 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT04517266?

Interventions in NCT04517266: omit of IMI group, IMI group.

What condition does NCT04517266 study?

NCT04517266 studies Breast Cancer.

Is NCT04517266 still recruiting?

NCT04517266 is currently recruiting now. Last updated 4 December 2023.

Last reviewed 2023-12-04 · How we verify

NCT04517266

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

Recruiting now NA Last updated 4 December 2023

What this trial tests

NA trial testing omit of IMI group in Breast Cancer in 214 participants. Currently enrolling.

Timeline

1 March 2021

Primary endpoint
30 October 2025

30 October 2030

Quick facts

Lead sponsor	Ruijin Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	214
Start date	1 March 2021
Primary completion	30 October 2025
Estimated completion	30 October 2030
Sites	1 location across China

Drugs / interventions tested

omit of IMI group
IMI group

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 80, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast cancer remains debated. The present study aimed to identified patient could be omitted from internal mammary lymph node irradiation by using a clinical-genomic model.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Tommasi C, Balsano R, Corianò M, Pellegrino B, et al · · 2022 · cited 36× · PMID 36498813 · DOI 10.3390/jcm11237239
IMNI PRECISION trial protocol: a phase II, open-label, non-inferior randomized controlled trial of tailoring omission of internal mammary node irradiation for early-stage breast cancer.
Qi WX, Cao L, Zheng S, Xu C, et al · · 2022 · cited 5× · PMID 36575421 · DOI 10.1186/s12885-022-10454-1
Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.
Xu Y, Qi Y, Lu Z, Tan Y, et al · · 2024 · cited 3× · PMID 39304993 · DOI 10.1080/15384047.2024.2405060
The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies.
Qi WX, Cao L, Xu C, Cai G, et al · · 2023 · PMID 36798812 · DOI 10.3389/fonc.2023.1081201

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04517266 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 4 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04517266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing